| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 | Form 4 |
| 12 Nov 2026 | 144 |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 |
Form 4: Cowan Elvia, SVP, Finance & CAO
Received 3,000 shares by exercise or conversion ($77.8K) · Sold 3,000 shares ($183K) |
| 04 Nov 2026 |
Form 4: Wassil Jim, EVP, Chief Scientific Ofc, COO
Received 2,250 shares by exercise or conversion ($12K) · Sold 2,250 shares ($137K) |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety Profile Similar to PCV20 and PCV21 Across All Ages St... |
| 02 Nov 2026 | 144 |
| 02 Nov 2026 | 144 |
| 09 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
FIRST SUPPLEMENTAL INDENTURE, dated as of October 9, 2026, between Vaxcyte, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), to the Base Indenture (as... |
| 08 Oct 2026 | 424B5 |
| 08 Oct 2026 | 424B5 |
| 07 Oct 2026 |
Form 4: Wassil Jim, EVP, Chief Scientific Ofc, COO
Received 18,000 shares by exercise or conversion ($96.3K) · Sold 18,000 shares ($1.56M) |
| 07 Oct 2026 |
Form 4: Cowan Elvia, SVP, Finance & CAO
Received 19,000 shares by exercise or conversion ($492K) · Sold 19,000 shares ($1.65M) |
| 07 Oct 2026 | FWP |
| 06 Oct 2026 | 305B2 |
| 06 Oct 2026 | 424B5 |
| 06 Oct 2026 | 424B5 |
Loading...